Abstract: To systematically summarize the progress of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) can accurately identify primary prostate lesions, lymph node micro metastases, and distant metastases. It performs significantly better than traditional imaging in early diagnosis, precise staging, locating biochemical recurrence, and treatment evaluation. It can revise the initial staging in 20%-30% of intermediate- to high-risk patients, with a detection rate exceeding 80% when serum prostate-specific antigen(PSA) is above 0.2 ng/mL. PSMA PET/CT has become a core imaging method for precision diagnosis and treatment of prostate cancer. Clinical practice should strictly follow guideline-based standards, and future developments are likely to focus on multimodal integration and combined targeted diagnosis and treatment.

Key words: prostate cancer, prostate-specific membrane antigen(PSMA), positron emission tomography/computed tomography(PET/CT), urology, precision diagnosis and treatment, tumor staging